FindTrial
Sign In

Add-on Treatment With Dehydroepiandrosterone (DHEA) and Its Treatment for Addiction

Add-on Treatment With Dehydroepiandrosterone (DHEA) and Its Effect on Quality of Life and Psychosocial Factors as Well as Epigenetic Markers -Dependent Addicts: A Double-blind, Randomized, Placebo-controlled Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-INR-17013698
Enrollment
Unknown
Registered
2017-12-05
Start date
2018-01-01
Completion date
Unknown
Last updated
2017-12-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

drug addiction

Interventions

2:PLACEBO
1:DHEA

Sponsors

Beijing High-tech Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 50 Years

Inclusion criteria

Inclusion criteria: 1. ICD-10 diagnosis of opioid dependence (World Health Organization, 1993); 2. Aged 18 - 50 years; 3. Written informed consent provision

Exclusion criteria

Exclusion criteria: 1. Serious kidney,lung,neurological and cardiovascular diseases; 2. Suicide risk, acute psychosis, severe depression, organic brain syndromes.

Design outcomes

Primary

MeasureTime frame
quality of life, cognitive function, psychosocial factors;—

Secondary

MeasureTime frame
self-perception;—

Countries

China

Contacts

Public ContactLi Gangyi

Beijing Epidia Medical Diagnosis technology Co., Ltd

gangyi_li@doingtimes.com+86 13901106501

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026